"The U.S. Food and Drug Administration today expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a second one.
This first-of-its-kind use is"...
Because thrombolytic therapy increases the risk of bleeding, Retavase® (reteplase) is contraindicated in the following situations:
- Active internal bleeding
- History of cerebrovascular accident
- Recent intracranial or intraspinal
- Intracranial neoplasm, arteriovenous
- Known bleeding diathesis
- Severe uncontrolled hypertension
Last reviewed on RxList: 9/15/2008
Additional Retavase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.